Drugs / cRGD-ZW800-1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05752149 | Jun 2025 → Feb 2027 expected | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma | Erasmus Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05518071 | Nov 2022 → May 2024 | cholangiocarcinoma, pancreatic adenocarcinoma | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04191460 | Jul 2022 → May 2025 overdue | oral cavity squamous cell carcinoma | Erasmus Medical Center | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-07 | Curadel Surgical Innovations, Inc. | Regulatory FDA and EMA Grant Orphan Drug Designation for Curadel’s CPI-008, a Targeted Zwitterionic Imaging Drug for Pancreatic Cancer curadelpharma.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-07 | Curadel Surgical Innovations, Inc. | FDA and EMA Grant Orphan Drug Designation for Curadel’s CPI-008, a Targeted Zwitterionic Imaging Drug for Pancreatic Cancer curadelpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cRGD-ZW800-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04191460 ↗ |
| Modality | Diagnostic / imaging agent | “intraoperative fluorescence imaging” NCT05752149 ↗ |
| Route | Intravenous | “Intravenous single bolus injection” NCT05518071 ↗ |